Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRiBRAVE: Ceralasertib priming plus durvalumab and nab-paclitaxel in advanced triple-negative breast cancer
2024-513721-23-00Phase 2Authorised
- Sponsor
- IFOM
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib, durvalumab and nab-paclitaxel in breast cancer, sponsored by IFOM. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
ceralasertibdurvalumabnab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-513721-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513721-23-00.